Sunday 22 December 2024

The Pharma Letter Podcast — Episode 19 — US midterms and beyond: outlook for pharma

Pharmaceutical
Simon Wentworth
28 November 2022
us-midterms-and-beyond-1

More on this story...

Pharmaceutical
The Pharma Letter Podcast — Episode 17 — Inflation Reduction Act: quick take
17 August 2022
Pharmaceutical
Biden-Harris Administration moves on affordable and accessible healthcare
27 October 2022
Pharmaceutical
Biden names Renee Wegrzyn as first head of ARPA-H
13 September 2022


More ones to watch >


Today's issue

Neurocrine Biosciences launches Crenessity in USA
Pharmaceutical
Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Biotechnology
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Biotechnology
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Biotechnology
Regeneron advances anticoagulant antibody program
20 December 2024
Pharmaceutical
Zealand blindsided by FDA rejection of glepaglutide
20 December 2024
Biotechnology
Astellas partners with Sangamo on cutting-edge gene therapy
20 December 2024
Biotechnology
Novartis to shut MorphSys sites amid pelabresib delay
20 December 2024

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.




More Features in Pharmaceutical

Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Zealand blindsided by FDA rejection of glepaglutide
20 December 2024
Novo Nordisk touts CagriSema success, but results miss expectations
20 December 2024
FDA approves Ionis’ Tryngolza
20 December 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze